½ÃÀ庸°í¼­
»óǰÄÚµå
1402029

¼¼°èÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå ¿¹Ãø(-2030³â) : À¯Çüº°, ¿¬·É´ëº°, ±â¼úº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®

Surrogacy Market Forecasts to 2030 - Global Analysis By Type, Age Group, Technology, End User and by Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é ¼¼°è ´ë¸®¸ð Ãâ»ê ½ÃÀåÀº 2023³â 2¾ï 1,034¸¸ ´Þ·¯·Î 2030³â¿¡´Â 3¾ï 6,282¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç ¿¹Ãø ±â°£ µ¿¾È 8.1%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

´ë¸®¸ð Ãâ»êÀ̶ó°í ºÒ¸®´Â »ý½Ä ÀÇ·á´Â ´ë¸®¸ð°¡ ´Ù¸¥ »ç¶÷À̳ª ºÎºÎ¸¦ ´ë½ÅÇØ ¾ÆÀ̸¦ ³º°í Ãâ»êÇÏ´Â °ÍÀÔ´Ï´Ù. Á¤»óÀûÀÎ ÀÓ½ÅÀÌ ÀÇÇÐÀûÀÎ Á¶°ÇÀ¸·Î ÀÎÇØ ¾î·Æ°Å³ª ºÒ°¡´ÉÇÒ ¶§ ÀÌ »ý½Ä º¸Á¶ ±â¼úÀÌ È°¿ëµË´Ï´Ù. ´ë¸®¸ð´Â ü¿Ü¼öÁ¤(IVF)À» ÅëÇØ ¼öÁ¤µÈ ¹è¾Æ¸¦ ´ë¸®¸ð°¡ ÀÓ½ÅÇÏ´Â ½ÃÇè°ü¾Æ±â ´ë¸®¸ð¿Í ´ë¸®¸ð°¡ ³­ÀÚ¸¦ Á¦°øÇÏ´Â ÀüÅëÀû ´ë¸®¸ð µÎ °¡Áö ÇüŰ¡ ÀÖ½À´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO)ÀÇ º¸°í¿¡ µû¸£¸é, °³¹ßµµ»ó±¹¿¡¼­´Â 4½Ö Áß 1½ÖÀÇ ºÎºÎ°¡ ºÒÀÓÀ» °æÇèÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àü ¼¼°èÀûÀ¸·Î ¸Å³â 6,000¸¸-8,000¸¸ ½ÖÀÇ ºÎºÎ°¡ ºÒÀÓ¿¡ ½Ã´Þ¸®°í ÀÖÀ¸¸ç, Àεµ¿¡¼­¸¸ 1,500¸¸-2,000¸¸ ½Ö(25%)ÀÌ ºÒÀÓ¿¡ ½Ã´Þ¸®°í ÀÖ½À´Ï´Ù.

Àνݳ¼±°ú ¼ö¿ë¼º Çâ»ó

»çȸÀûÀ¸·Î ºÒÀÓ ¹®Á¦¿¡ ´ëÇÑ Àνİú ¼ÖÁ÷ÇÑ ´ëÈ­°¡ Áõ°¡ÇÔ¿¡ µû¶ó ´ë¸®¸ð´Â ÇÕ¹ýÀûÀÌ°í ¹è·Á½É ÀÖ´Â »ý½Ä ¼±ÅÃÀ¸·Î ¹Þ¾Æµé¿©Áö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿ËÈ£ ´Üü, ÀÎÅÍ³Ý Æ÷·³ ¹× ±³À° ÇÁ·Î±×·¥Àº ´ë¸®¸ð¿¡ ´ëÇÑ ¿À¸íÀ» ¾ø¾Ö°í ºÒÀÓÀ¸·Î °í¹ÎÇÏ´Â µ¶½ÅÀÚ³ª ºÎºÎ¿¡°Ô ´õ °í¹«ÀûÀÎ ºÐÀ§±â¸¦ Á¶¼ºÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù.

´ë¸®¸ð Ãâ»êÀÇ ¼ö´Â ÇÑÁ¤

´ë¸®¸ð Ãâ»ê ½ÃÀåÀº ÀÇ¿åÀûÀ̰í ÀûÇÕÇÑ ´ë¸®¸ð ºÎÁ·À¸·Î ÀÎÇØ Å« Á¦¾àÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ÀÇÇÐÀû, ½É¸®Àû Á¶°ÇÀ» ÃæÁ·ÇÏ´Â ÀûÇÕÇÑ Èĺ¸ÀÚ¸¦ ã´Â µ¥ ¾î·Á¿òÀ» °ÞÀ» °æ¿ì, ´ë¸®¸ð¿Í ºÎ¸ð¸¦ ¸ÅĪÇÏ´Â °úÁ¤ÀÌ Áö¿¬µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ »çȸÀû Æí°ß, ÀáÀçÀû °Ç°­ À§Çè¿¡ ´ëÇÑ ¿ì·Á, ´ë¸®¸ð ÀýÂ÷ÀÇ ¾ö°ÝÇÔ µîÀÌ ´ë¸®¸ð ºÎÁ·ÀÇ ¿øÀÎÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

»ý½Ä ÀÇÇÐÀÇ ±â¼ú ¹ßÀü

À¯ÀüÀÚ °Ë»ç, ¹è¾Æ ¼±º°, Àΰø»ý½Ä ±â¼úÀÇ ¹ßÀü µî »ý½Ä ÀÇ·á ºÐ¾ßÀÇ Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ ´ë¸®¸ð Ãâ»ê ½ÃÀå¿¡´Â Å« ±âȸ°¡ Á¸ÀçÇÕ´Ï´Ù. ¶ÇÇÑ ´ë¸®¸ð¸¦ ¿øÇÏ´Â ºÎ¸ð¿¡°Ô ´ë¸®¸ð´Â ¼º°ø·ü Çâ»ó, ¹è¾Æ ¼±Åà °³¼±, °í±Þ ºÒÀÓ Ä¡·á¹ý °³¹ß·Î ÀÎÇØ ´ë¸®¸ð Ãâ»êÀÌ º¸´Ù Çö½ÇÀûÀÌ°í ºñ¿ë È¿À²ÀûÀÎ ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù.

±ÔÁ¦ÀÇ º¯È­¿Í ¹ýÀû ºÒÈ®½Ç¼º

´Ù¾çÇÑ °üÇÒ±ÇÀÇ ´Ù¾çÇÑ ´ë¸®¸ð °ü·Ã ¹ý·ü ü°è´Â ´ë¸®¸ð ¾÷°è¿¡ ½É°¢ÇÑ À§ÇèÀ» ÃÊ·¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹ý·üÀÇ ±Þ°ÝÇÑ º¯È­¿Í ¹ýÀû ¸ðÈ£¼ºÀº ´ë¸®¸ð ´Üü, ´ë¸®¸ð, ´ë¸®¸ð¿¡°Ô ¾î·Á¿òÀ» ÃÊ·¡ÇÏ°í ´ë¸®¸ð °è¾àÀÇ Áú¼­ ÀÖ´Â ÃßÁøÀ» ¹æÇØÇÒ ¼ö ÀÖ´Â ¹ýÀû °¥µî°ú ÇÕº´ÁõÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ:

COVID-19ÀÇ À¯ÇàÀº ´ë¸®¸ð Ãâ»ê ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃÄ º¸Á¶»ý½Ä¼ú ºÐ¾ß¿¡ ¾î·Á¿ò°ú È¥¶õÀ» °¡Á®¿Ô½À´Ï´Ù. Àü¿°º´À¸·Î ÀÎÇÑ ¿©Çà Á¦ÇѰú Æó¼â·Î ÀÎÇØ ´ë¸®¸ð °úÁ¤¿¡ Âü¿©ÇÏ·Á´Â ºÎ¸ð, ´ë¸®¸ð ¹× ÀÇ·á ¼­ºñ½º Á¦°øÀÚÀÇ ±¹Á¦ÀûÀÎ À̵¿À» ¹æÇØÇϰí ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀÎ °Ç°­ ¹®Á¦, º´¿ø Æó¼â, ºÒÀÓ Ä¡·á Áö¿¬À¸·Î ÀÎÇØ ´ë¸®¸ð ½Ã¼úÀÌ ÀϽÃÀûÀ¸·Î °¨¼ÒÇß½À´Ï´Ù. ¶ÇÇÑ Àü¿°º´ÀÌ °æÁ¦¿¡ ¹ÌÄ¡´Â ¿µÇâÀº ºÎ¸ð°¡ ´ë¸®¸ð ¼­ºñ½º¸¦¹ÞÀ» ¼öÀÖ´Â ´É·Â¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È ÀӽŠ´ë¸®¸ð ºÐ¾ß°¡ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»ó

º¸Á¶»ý½Ä¼ú Áß °¡Àå º¸ÆíÀûÀÌ°í ¼±È£µÇ´Â ¹æ¹ýÀÎ ´ë¸®¸ð´Â ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀӽŠ´ë¸®¸ð´Â ±âÁõÀÚ ¶Ç´Â ÀÓ½ÅÀ» ¿øÇÏ´Â ºÎ¸ð·ÎºÎÅÍ ³­ÀÚ¿Í Á¤ÀÚ¸¦ Á¦°ø¹Þ¾Æ ü¿Ü¼öÁ¤(IVF)À» ÅëÇØ ¹è¾Æ¸¦ ¸¸µå´Â ¹æ¹ýÀÔ´Ï´Ù. ÀÌ ¹æ¹ýÀº ´ë¸®¸ð¿Í ¾ÆÀÌ »çÀÌÀÇ À¯ÀüÀû ¿¬°áÀ» ²÷¾îÁÜÀ¸·Î½á Á¤¼­Àû, ¹ýÀû ¸íÈ®¼ºÀ» ´õ ¸¹ÀÌ °¡Á®¿É´Ï´Ù. ¶ÇÇÑ, »ý½Ä ±â¼úÀÇ ¹ßÀüÀ¸·Î ÀӽŠ´ë¸®¸ð´Â º¸´Ù ÅëÁ¦µÇ°í ¿¹Ãø °¡´ÉÇÑ °úÁ¤À¸·Î ³Î¸® Àνĵǰí ÀÖ½À´Ï´Ù.

ºÒÀÓ Å¬¸®´Ð ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»ó

´ë¸®¸ð Ãâ»ê ½ÃÀå¿¡¼­ °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÑ ºÎ¹®Àº ºÒÀÓ Å¬¸®´ÐÀÔ´Ï´Ù. ÃÖ÷´Ü »ý½Ä ¼­ºñ½º¸¦ Á¦°øÇÏ´Â À̵é Àü¹® Ŭ¸®´ÐÀº Áõ°¡ÇÏ´Â ºÒÀÓ ¹ß»ý·ü¿¡ ´ëÀÀÇÏ´Â µ¥ ÇʼöÀûÀÎ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ºÒÀÓ Àü¹® Ŭ¸®´ÐÀº öÀúÇÑ Áø´Ü Æò°¡, ü¿Ü¼öÁ¤(IVF)À» Æ÷ÇÔÇÑ ÃÖ÷´Ü º¸Á¶»ý½Ä¼ú(ART), ȯÀÚ¿Í ºÎºÎÀÇ Çʿ信 ¸Â´Â °³º°È­µÈ Ä¡·á ÇÁ·Î±×·¥À» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ART¿¡ ´ëÇÑ »çȸÀû ¼ö¿ëµµ°¡ ³ô¾ÆÁö°í ºÒÀÓ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ºÒÀÓŬ¸®´ÐÀÌ Á¦°øÇÏ´Â ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

°¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª

¼¼°è ´ë¸®¸ð Ãâ»ê ½ÃÀå¿¡¼­ ºÏ¹Ì Áö¿ªÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹°ú ij³ª´Ù¸¦ Æ÷ÇÔÇÑ ÀÌ Áö¿ªÀº Á¤±³ÇÑ ÀÇ·á ½Ã½ºÅÛ, ³ôÀº ÀÎÁöµµ, »ý½Ä ±â¼ú¿¡ ´ëÇÑ ´ë±Ô¸ð ÅõÀÚ·Î ÀÎÇØ ¿ìÀ§¸¦ Á¡Çϰí ÀÖ½À´Ï´Ù. º¸Á¶»ý½Ä¼ú(ART)¿¡ ´ëÇÑ ¹®È­Àû ¼ö¿ë¼º°ú ºÒÀÓ ¹®Á¦°¡ ³Î¸® ÆÛÁ® ÀÖ´Â °Íµµ ºÒÀÓ Ä¡·á ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ôÀº ÀÌÀ¯ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, ºÒÀÓ Ä¡·á ºÐ¾ßÀÇ ÁÖ¿ä Ŭ¸®´Ð, ¿¬±¸ ±â°ü ¹× ±â¼ú °³¹ßÀÌ ÀÌ Áö¿ª¿¡ ÁýÁߵǾî Àֱ⠶§¹®¿¡ »ý½Ä ÀÇ·á »ê¾÷¿¡¼­ ºÏ¹ÌÀÇ ÁÖ¿ä ±â¾÷À¸·Î¼­ÀÇ ÁöÀ§´Â ´õ¿í °­È­µÇ°í ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª:

¼¼°è ´ë¸®¸ð Ãâ»ê ½ÃÀå¿¡¼­ ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ °¡Àå ³ôÀº CAGRÀ» º¸À̰í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ »ý½Ä ÀÇ·á ¼­ºñ½º ¼ö¿ä´Â ºÒÀÓÀÇ À¯º´·ü Áõ°¡¿Í º¸Á¶»ý½Ä¼ú(ART)¿¡ ´ëÇÑ ÀÌÇØ¿Í ¼ö¿ëÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ±Þ°ÝÇÑ ¼ºÀåÀº ¶óÀÌÇÁ½ºÅ¸ÀÏÀÇ º¯È­, °¡Á·°èȹÀÇ ¹Ì·ç±â, »ý½Ä °Ç°­ÀÇ °³¼± µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ, ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ºÒÀÓ Ä¡·áÀÇ È®´ë¿Í ÀÇ·á ÀÎÇÁ¶óÀÇ °³¼±ÀÌ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

¹«·á ¸ÂÃãÇü ¼­ºñ½º

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½°ú °°Àº ¹«·á ¸ÂÃãÇü ¿É¼Ç Áß Çϳª¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù:

  • ȸ»ç ÇÁ·ÎÇÊ
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕÀûÀÎ ÇÁ·ÎÆÄÀϸµ(ÃÖ´ë 3°³»ç±îÁö)
    • ÁÖ¿ä ±â¾÷ SWOT ºÐ¼®(3°³»ç±îÁö)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ µû¸¥ ÁÖ¿ä ±¹°¡º° ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø, CAGR(Âü°í: Ÿ´ç¼º °ËÅä¿¡ µû¸¥)
  • °æÀï»ç º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¸®Àû ÀÔÁö, Àü·«Àû Á¦ÈÞ¸¦ ±â¹ÝÀ¸·Î ÇÑ ÁÖ¿ä ±â¾÷ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

  • °³¿ä
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç Á¢±Ù¹ý
  • Á¶»ç ¼Ò½º
    • 1Â÷ Á¶»ç ¼Ò½º
    • 2Â÷ Á¶»ç ¼Ò½º
    • °¡Á¤

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • ±â¼ú ºÐ¼®
  • ÃÖÁ¾»ç¿ëÀÚ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ¿µÇâ

Á¦4Àå Porter's Five Forces ºÐ¼®

  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
  • °æÀï ±â¾÷ °£ÀÇ °æÀï °ü°è

Á¦5Àå ¼¼°èÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå : À¯Çüº°

  • ÀӽŠ´ë¸®¸ð Ãâ»ê
  • ±âÁ¸ ´ë¸®¸ð Ãâ»ê
  • ±âŸ À¯Çü

Á¦6Àå ¼¼°èÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå : ¿¬·ÉÃþº°

  • 35¼¼ ¹Ì¸¸
  • 35-37¼¼
  • 38-39¼¼
  • 40-42¼¼
  • 43-44¼¼
  • 44¼¼ ÀÌ»ó

Á¦7Àå ¼¼°èÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå : ±â¼úº°

  • Àڱó» ¼öÁ¤(IUI)
  • ü¿Ü¼öÁ¤(IVF)
    • Ŭ·¡½Ä/½ºÅÄ´Ùµå ü¿Ü¼öÁ¤
    • ¼¼Æ÷Áú³» Á¤ÀÚ ÁÖÀÔ(ICSI)
  • ±âŸ ±â¼ú

Á¦8Àå ¼¼°èÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • ºÒÀÓ Å¬¸®´Ð
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦9Àå ¼¼°èÀÇ ´ë¸®¸ð Ãâ»ê ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ÁÖ¿ä ¹ßÀü

  • °è¾à, ÆÄÆ®³Ê½Ê, Çù¾÷, ÇÕÀÛÅõÀÚ
  • Àμö¿Í ÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦11Àå ±â¾÷ °³¿ä

  • Extraordinary Conceptions
  • Boston IVF
  • Growing Generations LLC
  • IVIRMA Global
  • Max Healthcare
  • New Hope Fertility Center
  • Bourn Hall International
  • Houston Fertility Center
  • Circle Surrogacy & Egg Donation
  • Nova Ivi Fertility
  • Ovation Fertility
  • Scanfert Clinic
  • Care Fertility Group
ksm 24.01.11

According to Stratistics MRC, the Global Surrogacy Market is accounted for $210.34 million in 2023 and is expected to reach $362.82 million by 2030 growing at a CAGR of 8.1% during the forecast period. A surrogate woman bears and gives birth to a child on behalf of another person or couple in a reproductive arrangement known as surrogacy. When conventional conception is difficult or impossible due to medical conditions, this assisted reproductive technology is used. Moreover, the two main forms of surrogacy are gestational surrogacy, in which the surrogate carries an embryo fertilized by in vitro fertilization (IVF), usually using the genetic material of the intended parents or donors, and traditional surrogacy, in which the surrogate contributes her egg.

According to a report by the World Health Organization (WHO), one in four couples in developing nation's experiences infertility. Additionally, 60-80 million couples worldwide suffer from infertility each year, with 15-20 million (25%) residing in India alone.

Market Dynamics:

Driver:

Raising awareness and acceptance

Growing awareness campaigns and a more candid conversation about fertility issues in society are supporting surrogacy's growing acceptance as a legal and compassionate reproductive option. Additionally, advocacy groups, internet forums, and educational programs help dispel the stigmas surrounding surrogacy and create a more encouraging atmosphere for single people and couples dealing with infertility.

Restraint:

Limited number of surrogates available

The surrogacy market is significantly constrained by the lack of willing and suitable surrogates. The process of matching intended parents with surrogates can be delayed when appropriate candidates who fulfill both medical and psychological requirements are difficult to find. Furthermore, social stigmas, worries about potential health hazards, or the rigorous requirements of the surrogacy procedure could all contribute to this shortage.

Opportunity:

Technological progress in reproductive health

Significant opportunities exist for the surrogacy market as a result of ongoing technological advancements in reproductive medicine, such as advances in genetic testing, embryo screening, and artificial reproductive techniques. Moreover, for intended parents, surrogacy is becoming a more practical and cost-effective option thanks to increased success rates, improved embryo selection, and the development of more advanced fertility treatments.

Threat:

Regulation changes and legal uncertainties

Diverse legal frameworks for surrogacy across different jurisdictions present a serious risk to the surrogacy industry. Additionally, swift alterations in laws or legal ambiguities could pose difficulties for surrogacy organizations, intended parents, and surrogates, resulting in possible legal conflicts and complications that could hinder the orderly advancement of surrogacy agreements.

COVID-19 Impact:

The COVID-19 pandemic has had a major effect on the surrogacy market and brought difficulties and disturbances to the assisted reproductive sector. Travel restrictions and lockdowns brought on by the pandemic have hindered the international mobility of intended parents, surrogates, and healthcare providers participating in the surrogacy process. There has been a brief decrease in surrogacy procedures due to ongoing health concerns, clinic closures, and delays in fertility treatments. Furthermore, the pandemic's effects on the economy could have an impact on intended parents' ability to afford surrogacy services.

The Gestational Surrogacy segment is expected to be the largest during the forecast period

As the most common and favored method of assisted reproduction, gestational surrogacy commands the largest share of the market. When a person is used in a gestational surrogacy, their eggs and sperm from donors or the intended parents are used to create an embryo through in vitro fertilization (IVF). This approach provides more emotional and legal clarity by severing genetic ties between the surrogate and the child. Moreover, reproductive technology advancements have made gestational surrogacy more widely recognized as a more controlled and predictable process.

The Fertility Clinics segment is expected to have the highest CAGR during the forecast period

In the surrogacy market, the segment with the highest CAGR is fertility clinics. These specialist clinics, which provide a range of cutting-edge reproductive services, are essential in tackling the growing incidence of infertility. Fertility clinics offer thorough diagnostic evaluations, state-of-the-art assisted reproductive technologies (ART), including in vitro fertilization (IVF), and individualized treatment programs made to meet each patient's or couple's specific needs. Additionally, the demand for the services provided by fertility clinics has increased due to rising societal acceptance of ART and increased awareness of fertility issues.

Region with largest share:

In the global surrogacy market, North America holds the largest share. Because of its sophisticated healthcare system, high level of awareness, and large investments in reproductive technologies, this region-which includes the United States and Canada-dominates. The high demand for fertility services is partly due to the cultural acceptance of assisted reproductive technologies (ART) and the prevalence of infertility problems. Moreover, North America's status as a major player in the reproductive healthcare industry is further cemented by the region's concentration of top fertility clinics, research institutes, and technological developments in the field.

Region with highest CAGR:

In terms of the global market for surrogacy, the Asia-Pacific region has the highest CAGR. The demand for reproductive services in Asia-Pacific is driven by the rising prevalence of infertility as well as increased understanding and acceptance of assisted reproductive technologies (ART). The region's rapid growth is caused by a number of factors, including evolving lifestyles, postponing family planning, and improvements in reproductive health. Furthermore, expanding fertility treatments and better healthcare infrastructure in Asia-Pacific nations support the market's growth.

Key players in the market:

Some of the key players in Surrogacy market include Extraordinary Conceptions, Boston IVF, Growing Generations LLC, IVIRMA Global, Max Healthcare, New Hope Fertility Center, Bourn Hall International, Houston Fertility Center, Circle Surrogacy & Egg Donation, Nova Ivi Fertility, Ovation Fertility, Scanfert Clinic and Care Fertility Group.

Key Developments:

In November 2023, IVI RMA, one of the largest reproductive medicine groups in the world, has signed a definitive agreement to acquire the North American Operations of Eugin Group, consisting of the Boston IVF fertility network and Toronto-based TRIO, from healthcare group Fresenius. The strategic additions will grow IVI RMA to become a leading fertility group in North America and reinforce the company's commitment to providing evidence-based fertility solutions with the greatest chance of success to the greatest number of patients.

In October 2023, Boston IVF, a renowned leader in fertility research and patient care since its establishment in 1986, is proud to announce its substantial participation in the 2023 American Society for Reproductive Medicine (ASRM) Scientific Congress and Expo. This prestigious annual event, in New Orleans, Louisiana, from October 14-18, brought together global experts to share groundbreaking advancements in technology, treatments, and patient care in reproductive medicine.

Types Covered:

  • Gestational Surrogacy
  • Traditional Surrogacy
  • Other Types

Age Groups Covered:

  • Below 35 Years
  • 35-37 Years
  • 38-39 Years
  • 40-42 Years
  • 43-44 Years
  • Over 44 Years

Technologies Covered:

  • Intrauterine Insemination (IUI)
  • In-vitro Fertilization (IVF)
  • Other Technologies

End Users Covered:

  • Hospitals
  • Fertility Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Surrogacy Market, By Type

  • 5.1 Introduction
  • 5.2 Gestational Surrogacy
  • 5.3 Traditional Surrogacy
  • 5.4 Other Types

6 Global Surrogacy Market, By Age Group

  • 6.1 Introduction
  • 6.2 Below 35 Years
  • 6.3 35-37 Years
  • 6.4 38-39 Years
  • 6.5 40-42 Years
  • 6.6 43-44 Years
  • 6.7 Over 44 Years

7 Global Surrogacy Market, By Technology

  • 7.1 Introduction
  • 7.2 Intrauterine Insemination (IUI)
  • 7.3 In-vitro Fertilization (IVF)
    • 7.3.1 Classical/Standard IVF
    • 7.3.2 Intracytoplasmic Sperm Injection (ICSI)
  • 7.4 Other Technologies

8 Global Surrogacy Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Fertility Clinics
  • 8.4 Other End Users

9 Global Surrogacy Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Extraordinary Conceptions
  • 11.2 Boston IVF
  • 11.3 Growing Generations LLC
  • 11.4 IVIRMA Global
  • 11.5 Max Healthcare
  • 11.6 New Hope Fertility Center
  • 11.7 Bourn Hall International
  • 11.8 Houston Fertility Center
  • 11.9 Circle Surrogacy & Egg Donation
  • 11.10 Nova Ivi Fertility
  • 11.11 Ovation Fertility
  • 11.12 Scanfert Clinic
  • 11.13 Care Fertility Group
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦